Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Bayer Aktienges ADR (BAYRY)

Bayer Aktienges ADR (BAYRY)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
5.4800 +0.0300 (+0.55%) 04/08/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 5.4800 unch (unch) 15:59 ET
Quote Overview for Tue, Apr 8th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
5.4100
Day High
5.7200
Open 5.7100
Previous Close 5.4500 5.4500
Volume 745,700 745,700
Avg Vol 596,460 596,460
Stochastic %K 9.62% 9.62%
Weighted Alpha -26.11 -26.11
5-Day Change -0.5700 (-9.42%) -0.5700 (-9.42%)
52-Week Range 4.7900 - 8.5800 4.7900 - 8.5800
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 21,534,736
  • Shares Outstanding, K 3,929,696
  • Annual Sales, $ 50,432 M
  • Annual Income, $ -2,762 M
  • EBIT $ -77 M
  • EBITDA $ 9,427 M
  • 60-Month Beta 0.93
  • Price/Sales 0.42
  • Price/Cash Flow 1.45
  • Price/Book 0.62
  • Price/Earnings ttm 3.98
  • Earnings Per Share ttm 1.37
  • Most Recent Earnings $0.28 on 03/05/25
  • Next Earnings Date 05/13/25
  • Annual Dividend & Yield 0.02 (0.40%)
  • Most Recent Dividend 0.022 on 04/29/24
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.47
  • Number of Estimates 2
  • High Estimate 0.57
  • Low Estimate 0.38
  • Prior Year 0.77
  • Growth Rate Est. (year over year) -38.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.3000 +3.40%
on 04/07/25
Period Open: 6.3600
6.8300 -19.77%
on 03/18/25
-0.8800 (-13.84%)
since 03/07/25
3-Month
5.0100 +9.38%
on 01/14/25
Period Open: 5.0600
6.8300 -19.77%
on 03/18/25
+0.4200 (+8.30%)
since 01/08/25
52-Week
4.7900 +14.41%
on 12/24/24
Period Open: 7.4600
8.5800 -36.13%
on 09/30/24
-1.9800 (-26.54%)
since 04/08/24

Most Recent Stories

More News
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus (ocrelizumab).The company announced that a phase III study, MUSETTE, which compared...

BAYRY : 5.4800 (+0.55%)
GILD : 103.19 (-2.21%)
REGN : 556.81 (-2.79%)
RHHBY : 35.9000 (-0.28%)
FDA Grants Accelerated Approval to NVS Kidney Disease Drug

Novartis NVS obtains FDA approval of atrasentan, a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN)...

BAYRY : 5.4800 (+0.55%)
NVS : 101.96 (-0.88%)
GILD : 103.19 (-2.21%)
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce...

BAYRY : 5.4800 (+0.55%)
CORT : 70.49 (-5.57%)
ALNY : 224.32 (-3.70%)
SNY : 49.86 (-1.77%)
J&J's Third Bankruptcy Attempt to End Talc Suits Rejected

Johnson & Johnson JNJ announced that a bankruptcy court in Texas has rejected its bankruptcy plan to resolve talc lawsuits for the third time.J&J faces more than 62,000 lawsuits for its talc-based products,...

BAYRY : 5.4800 (+0.55%)
JNJ : 150.00 (-0.41%)
GILD : 103.19 (-2.21%)
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib).The regulatory body approved Cabometyx for the treatment of adult and pediatric patients...

BAYRY : 5.4800 (+0.55%)
NVO : 61.60 (-3.21%)
EXEL : 34.13 (-2.04%)
BMY : 53.07 (-3.84%)
Bayer Enters License Agreement With China’s Puhe BioPharma For Cancer Drug Candidate: Retail Stays Bullish

Bayer’s Pharmaceuticals Division’s Head of Business Development and Licensing Juergen Eckhardt said the drug’s “highly selective targeting” of cancer cells while sparing healthy ones is “very...

BAYRY : 5.4800 (+0.55%)
Bayer Down on Verdict to Pay $2.1B to Plaintiff in Roundup Litigation

Shares of pharma conglomerate Bayer BAYRY were down 7.1% on March 24, following a setback in the ongoing Roundup Litigation.Bayer reported that, on March 21, the jury at the Barnes Roundup trial in the...

BAYRY : 5.4800 (+0.55%)
NVO : 61.60 (-3.21%)
GILD : 103.19 (-2.21%)
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%

Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This update allows cash-paying patients or those with commercial insurance, which does...

BAYRY : 5.4800 (+0.55%)
NVO : 61.60 (-3.21%)
LLY : 726.24 (+0.35%)
GILD : 103.19 (-2.21%)
5 Large Drug Stocks to Watch as Industry Recovers

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due to the better-than-expected fourth-quarter performance of large drugmakers and...

BAYRY : 5.4800 (+0.55%)
NVO : 61.60 (-3.21%)
NVS : 101.96 (-0.88%)
ABBV : 175.67 (-5.83%)
PFE : 21.84 (-3.49%)
FDA Approves Novartis Drug for Rare Kidney Disease Treatment

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication.The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria.C3G...

BAYRY : 5.4800 (+0.55%)
NVS : 101.96 (-0.88%)
GILD : 103.19 (-2.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses....

See More

Key Turning Points

3rd Resistance Point 5.9733
2nd Resistance Point 5.8467
1st Resistance Point 5.6633
Last Price 5.4800
1st Support Level 5.3533
2nd Support Level 5.2267
3rd Support Level 5.0433

See More

52-Week High 8.5800
Fibonacci 61.8% 7.1322
Fibonacci 50% 6.6850
Fibonacci 38.2% 6.2378
Last Price 5.4800
52-Week Low 4.7900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades